Differenzierung von malignen und nichtmalignen, inflammatorischen Perikardergüssen mit Biomarkern

Karatolios, Konstantinos; Alter, Peter; Maisch, Bernhard

doi:10.1007/s00059-009-3304-8

Cited by 7 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the magnitude of this serious problem, little progress has been made in the treatment of pericardial effusion secondary to malignant disease [3]. …”

Section: Introductionmentioning

confidence: 99%

Malignant Pericardial Effusion

Burazor

Imazio

Markel³

et al. 2013

Cardiology

106

View full text Add to dashboard Cite

Malignant pericardial effusion is a common and serious manifestation in malignancies. The origins of the malignant process include solid tumors or hematological malignancies, while primary neoplasms of the pericardium are less common. In the oncological patient, pericardial effusion may develop by several different mechanisms, namely by direct or metastatic spread of the primary process or as a complication of antineoplastic therapies. In some cases, pericardial effusion may be the first manifestation of the disease, and that is why malignancy must be excluded in every case of an acute pericardial disease with cardiac tamponade at presentation, rapidly increasing pericardial effusion and an incessant or recurrent course. Thus, the definite differentiation of malignant pericardial effusion and rapid diagnosis are of particular therapeutic and prognostic importance. Management of these patients is multidisciplinary and requires team work, but at present there is a need for further research. An individual treatment plan should be established, taking into account cancer stage, the patient's prognosis, local availability and experience. In emergency cases with cardiac tamponade or significant effusion, initial relief can be obtained with pericardiocentesis. Despite the magnitude of this serious problem, little progress has been made in the treatment of pericardial effusion secondary to malignant disease.

show abstract

“…Despite the magnitude of this serious problem, little progress has been made in the treatment of pericardial effusion secondary to malignant disease [3]. …”

Section: Introductionmentioning

confidence: 99%

Malignant Pericardial Effusion

Burazor

Imazio

Markel³

et al. 2013

Cardiology

106

View full text Add to dashboard Cite

show abstract

“…Metastatic tumors, especially lung and breast cancer, esophageal squamous cell carcinoma, malignant melanoma, thymic carcinoma, kidney, bladder malignancies as well as mesenchymal tumors like Ewing's sarcoma or hematological malignancies (mostly leukemia, non-Hodgkin's lymphoma and Hodgkin's lymphoma) are the most common causes for pathological PE (7) . Primary tumors of the pericardium such as mesothelioma, fibrosarcoma, lymphangioma, hemangioma, teratoma, neurofibroma and lipomas are rare (8) . The third most common cause is infection and it is often viral.…”

Section: Discussionmentioning

confidence: 99%

Could the cytological evaluation of pericardial effusions illuminate our path?

Ekmekçi¹,

Ekmekçi²,

Dere³

et al. 2018

Terh

View full text Add to dashboard Cite

Objective: Pericardial effusion (PE) is a common clinical condition that can develop as a result of systemic or heart disease. In our study, we synthesized the cytopathological and clinical results of patients who underwent pericardiocentesis due to pericardial effusion. Method: A total of 213 patients who underwent percutaneous pericardiocentesis between 2007-2017 were included in the study: their cytologic and histopathologic diagnoses were noted and their relations were examined. Results: Hundred and thirty-two cases were male (61.9%), 81 were female (38.1%) and the mean of the study population age was 59.9 (min 13-max 97) years. Hundred and sixty-eight patients had benign (78.9%), 10 suspicious (4.6%), 3 non-diagnostic (1.4%) and 32 malignant cytologies (15.1%). Benign pericardial effusion was the most common diagnosis. Malignant cytology findings were interpreted as lung carcinoma (n=20: 62.5%), rhabdomyosarcoma (n=1: 3.1%), poorly differentiated adenocarcinoma (n=2: 6.2%), a gastrointestinal system carcinoma (n=4: 12.5%), undifferentiated epithelial tumor (n=1: 3.1%), breast carcinoma (n=1: 3.1%), and unspecified malignant tumor (n=3: 9%). Four (2.4%) of the 168 patients having diagnosis of benign cytology had previously received diagnosis of a malignant disease, however examination of cytological specimen. Did not reveal any malignancy. Three (30%) of the 10 patients with suspicious cytology, had received diagnosis of a malignant disease previously. Conclusion:In developed countries, it is reported that more than 50% of the PE's are idiopathic. The percentage of cancer-associated PE's is 10-25%. In our study, 78.9% of our cases had a benign diagnosis, and 15.1% had malignant PE consistent with the literature findings. Cytological sampling in pericardial fluid is a method that can shed light on the diagnosis of many diseases.

show abstract

“…Assessment of left-ventricular systolic function, myocardial perfusion imaging to detect ischemic complications, as well as cardiac biomarkers like troponin I, and T, B-type natriuretic peptide might also be considered in selected patient populations at high risk [35,36,38,44]. These investigations will be useful to anticipate cardio-specific treatment and decide on the most appropriate pharmacological therapy for congestive heart failure at early onset [26].…”

Section: Pre-and Post-therapeutic Assessment Of Cardiovascular Risk Amentioning

confidence: 99%